Clinical trial
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
NCT00001261 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00001261 |
|---|---|
| Title | Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies |
| Official title | The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dermatomyositis, Inclusion Body Myositis, Polymyositis |
| Intervention type | Drug |
| Interventions | Gamma Globulin |
| Enrollment | 120 |
| Start date | May 1, 1990 |
| Completion | Jul 1, 2002 |
| First posted | Nov 4, 1999 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: